Stocks / MRNA
MRNA stock forecast
MODERNA INC · Healthcare · Biotechnology
The model's rating
Greatly Underperform
MRNA is rated Greatly Underperform as of September 29, 2026: its medium-term return forecast is in the bottom fifth of the stocks the model scores.
Create a free account to compare any two stocks; the numeric score is part of Premium.
MRNA is not among the 20 largest holdings published for 2026 Q4. See the portfolio
MRNA against the S&P 500
| Period | MRNA | S&P 500 (SPY) |
|---|---|---|
| 1 month | +37.2% | -0.3% |
| 3 months | +165.6% | +2.5% |
| Year to date | +553.0% | +12.7% |
| 1 year | +645.5% | +15.7% |
Total return, dividends included.
Key numbers
| Price | $192.57 |
| Market cap | 76.88 Billion |
| P/E (trailing 12 months) | -24.1 |
| P/S (trailing 12 months) | 34.5 |
| P/B (latest quarter) | 3.2 |
| Gross margin | 23.4% |
| Net profit margin | -141.4% |
| Return on equity | -39.2% |
| Beta | 2.0 |
As of July 31, 2026.
MRNA and its closest peers
| Stock | Company | Market cap | Model rating | |
|---|---|---|---|---|
| REGN | REGENERON PHARMACEUTICALS INC | 78.07 Billion | Greatly Outperform | REGN vs MRNA |
| INCY | INCYTE CORP | 24.6 Billion | Greatly Outperform | MRNA vs INCY |
| VRTX | VERTEX PHARMACEUTICALS INC | 132.51 Billion | Outperform | VRTX vs MRNA |
| TECH | BIO-TECHNE CORP | 11.36 Billion | Greatly Underperform | MRNA vs TECH |
Questions
What does the Upfront Investment model say about MRNA?
The model rates MODERNA INC (MRNA) "Greatly Underperform" as of September 29, 2026, which means its medium-term return forecast is in the bottom fifth of the stocks the model scores. The rating is a statistical forecast, not a recommendation to buy or sell.
How is the MRNA rating produced?
A machine-learning model forecasts each stock's return over the coming months and ranks the forecasts against each other. The label says where this stock's forecast falls in that ranking. It is refreshed whenever the model's data updates, normally every trading day.
Is MRNA in the Upfront Investment model portfolio?
MRNA is not among the 20 largest holdings published for 2026 Q4.
The rating is the output of a statistical model and can be wrong. It is not investment advice and takes no account of your circumstances. Past performance does not guarantee future results.